Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Revenue under licensing agreements		$ 925	$ 0
Operating expenses:
Research and development expenses		60,917	44,394
General and administrative expenses		22,613	11,189
Total operating expenses		83,530	55,583
Loss from operations		(82,605)	(55,583)
Other income (expense):
Interest income		8,467	2,951
Interest expense		(12)	(12)
Other income		574	16,355
Other expense		(1,568)	(28)
Net loss		$ (75,144)	$ (36,317)
Per share information
Net income (loss) per share, basic (in dollars per share)		$ (4.28)
Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares)		17,567,082
Net income (loss) per share, diluted (in dollars per share)		$ (4.28)
Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares)		17,567,082
Class A Common Stock
Per share information
Net income (loss) per share, basic (in dollars per share)	[1]	$ (4.28)
Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares)	[1]	17,567,082
Net income (loss) per share, diluted (in dollars per share)	[1]	$ (4.28)
Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares)	[1]	17,567,082

[1]     On December 18, 2023, the Company completed its reverse merger, which among other things, resulted in Neurogene OpCo merging with and into a wholly owned subsidiary of Neoleukin Therapeutics, Inc. As the earnings per share information for the pre-merger period is not comparable to the earnings per share information for the post-merger period, the earnings per share information is being presented separately for these periods. See Note 3, Net Income (Loss) Per share, for additional information. (a)Presents information for the pre-merger period for Class A common stock. The pre-merger period is January 1, 2023 through December 17, 2023 for the year ended December 31, 2023. (b)Presents information for the pre-merger period for Class B common stock. The pre-merger period is January 1, 2023 through December 17, 2023 for the year ended December 31, 2023. (c)Presents information for the post-merger period for common stock. The post-merger period is December 18, 2023 through December 31, 2023.